Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Particle Sciences (PSI), a pharmaceutical CRO, has acquired the exclusive rights to drug delivery technology company Lyotropic Therapeutics' (LTI) LyoCell patent portfolio, under a revenue-share agreement.
Subscribe to our email newsletter
The LyoCell technology allows for the solubilization, stabilization, and delivery of a wide range of compounds – both small and large molecule.
As per the agreement, PSI obtains a full license to the technology except for several compounds previously developed by LTI, in addition to inclusion of intellectual property around the stabilization of macromolecules.
PSI clients looking to increase bioavailability or develop parenteral formulations of difficult-to-solubilize compounds can now utilize the LTI technology.
Particle Sciences VP Pharmaceutical Development Robert Lee said LyoCells are proprietary lyotropic liquid crystal-based formulations that contain both polar and non-polar nano-domains.
"These unique structures create ideal conditions for the solubilization and stabilization of many pharmaceuticals and biopharmaceuticals," Lee said.
"Made from GRAS ingredients, this technology is already in late stage clinical development in an intravenous product and has applications in most routes of administration."
Lyotropic Therapeutics CEO Vince Conklin said:"The LyoCell technology has proven to be highly effective in solving very difficult formulation problems and is the basis for several drugs now in or poised to enter the clinical stage."